skip to main content
covidend_logo_color

Our network of sites

Scan evidence products

 

Evidence products prepared or updated with funding from COVID-END in Canada can be accessed below. These evidence products are shared through our twice-a-month Canadian spotlights and through many of our dissemination partners. If you want to receive an email containing hyperlinks to our Canadian (and global) spotlights twice a month, subscribe here.

Question (and request #) Product type Date (and product #) Plain-language summary
How can we support crisis management and renewal in long-term care? (#8)  Living evidence profile In progress  
What are the implications of SARS-CoV-2 variants for public-health measures, clinical management and health-system arrangements? (#7)
Rapid synthesis In progress   
Can people who are vaccinated develop asymptomatic COVID-19 infection and transmit the virus to other individuals?  If so, how large is the risk, in comparison to unvaccinated people and among those infected with SARS-CoV-2 variants? (#5)
Living evidence synthesis
In progress   
What is known about anticipated COVID-19 vaccine roll-out elements? (#1)
Living evidence profile

2021-02-11 (LEP 1.3)

Past versions

In progress

  • English
  • French
What factors affect health workers’ attitudes toward vaccination uptake and what strategies have been successful in increasing vaccination among health workers? (#6)
Response based on existing resources  2021-02-04 (Response 6) 

In progress

  • English
  • French
Can people who are vaccinated develop asymptomatic COVID-19 infection and transmit the virus to other individuals and, if so, how large is the risk compared to unvaccinated people? (#4)
Response based on existing resources

2021-02-04 (Response 4)

See request #6 for additional work

In progress

  • English
  • French
What do we know from both research and jurisdictional scans about prioritizing vaccination of asymptomatic residents in a long-term care home with an outbreak? (#3)
Rapid evidence profile
2021-01-20 (REP 25)

In progress

  • English
  • French
How can we best leverage existing resources to provide evidence-based advice on COVID-19 therapeutics and issue guidance statements to inform decision makers and healthcare professionals on the use of pharmaceuticals for the treatment or chemoprophylaxis of COVID-19? (#2)
Response based on existing resources  2020-12-20 (Response 2)

In progress

  • English
  • French

Our evidence products can take many forms:

  • response based on existing resources
  • one-off rapid evidence profile or rapid synthesis
  • living evidence profile or living evidence synthesis that is updated regularly.

Our evidence profiles and evidence syntheses vary in:

  • the effort that goes into them, which we measure in the number of hours or days that a very large team of highly experienced staff devote exclusively to the task (e.g., four hours to three days for evidence profiles and for updates to living evidence profiles; five to ten days for rapid syntheses and for updates to living evidence syntheses)
  • the type of best evidence they include and whether they also include a jurisdictional scan.

Below we provide examples of how these evidence products can vary.

Product type Best evidence Jurisdictional scan 
Rapid evidence profile (four hours) Profile of existing evidence syntheses
1-2 provinces and 1-2 countries
Rapid evidence profile (1 day)
Same but with more decision-relevant information extracted and quality rating of evidence syntheses
3-4 provinces and 3-4 countries
Rapid evidence profile (2 days)
Same but with even more decision-relevant information extracted
5-6 provinces and 5-6 countries
Rapid evidence profile (3 days)
Same plus profile of singles studies
All Canadian jurisdictions and up to 10 countries
Rapid review – Scoping (5-10 days)
Inventory of syntheses and single studies
No
Rapid review – Overview (5-10 days)
Overview of syntheses with quality ratings
No
Rapid review – Synthesis (5-10 days)
Synthesis of single studies with risk-of-bias assessment
No